Hazai tapasztalatok metasztatikus kolorektális karcinóma bevacizumabbal kiegészített indukciós kemoterápiás kezelésével (AVACONT vizsgálat)
The primary aim of AVACONT was to collect data in the course of routine oncological care from patients with metastatic colorectal cancer (mCRC) treated with bevacizumab supplemented fluoropyrimidine-based chemotherapy doublet in an open, multicentre, observational study in Hungary. Primary endpoint...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2022
|
| Sorozat: | MAGYAR ONKOLÓGIA
66 No. 1 |
| Tárgyszavak: | |
| mtmt: | 32768234 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/28578 |
| LEADER | 02134nab a2200313 i 4500 | ||
|---|---|---|---|
| 001 | publ28578 | ||
| 005 | 20231107091806.0 | ||
| 008 | 231107s2022 hu o 0|| Magyar d | ||
| 022 | |a 0025-0244 | ||
| 024 | 7 | |a 32768234 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Magyar | ||
| 100 | 1 | |a Landherr László | |
| 245 | 1 | 0 | |a Hazai tapasztalatok metasztatikus kolorektális karcinóma bevacizumabbal kiegészített indukciós kemoterápiás kezelésével (AVACONT vizsgálat) |h [elektronikus dokumentum] / |c Landherr László |
| 260 | |c 2022 | ||
| 300 | |a 11-19 | ||
| 490 | 0 | |a MAGYAR ONKOLÓGIA |v 66 No. 1 | |
| 520 | 3 | |a The primary aim of AVACONT was to collect data in the course of routine oncological care from patients with metastatic colorectal cancer (mCRC) treated with bevacizumab supplemented fluoropyrimidine-based chemotherapy doublet in an open, multicentre, observational study in Hungary. Primary endpoint of the study was to determine progression-free survival (PFS). The Full Analysis Set (FAS) comprised 280 patients. Median PFS calculated from enrolment was 270 days in the FAS population. The metastatic involvement of the liver or more than one organ significantly decreased (250 and 245 days), while a clinical response achieved significantly increased (partial response: 404, complete response: 623 days) the mPFS calculated from enrolment. PFS calculated from the start of the first-line treatment was significantly decreased by the presence of mutant RAS gene (481 vs. 395 days). The results confirm the efficacy, known prognostic factors and safety profile of bevacizumab in combination with chemotherapy dosed during standard oncology care in Hungarian centres. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Pintér Tamás |e aut |
| 700 | 0 | 1 | |a Hornyák Lajos |e aut |
| 700 | 0 | 1 | |a Révész János |e aut |
| 700 | 0 | 1 | |a Máhr Károly |e aut |
| 700 | 0 | 1 | |a Torday László |e aut |
| 700 | 0 | 1 | |a András Csilla |e aut |
| 700 | 0 | 1 | |a Erfán József |e aut |
| 700 | 0 | 1 | |a Árkosy Péter |e aut |
| 700 | 0 | 1 | |a Bodoky György |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/28578/1/0011a.pdf |z Dokumentum-elérés |